Treatment options for COVID-19
A Review of Pertinent Drug Information for SARS-CoV-2 from the Society of Infectious Diseases Pharmacists (SIDP)
Jason M. Pogue, PharmD, BCPS, BCIDP
President, Society of Infectious Diseases Pharmacists
Clinical Professor, University of Michigan College of Pharmacy, Ann Arbor, MI
@jpogue1

What will be coming
• Detailed reviews of the main therapeutic options for COVID-19
• In vitro, animal, and clinical data (if available) against zoonotic coronaviruses
• Key pharmacological considerations
• Adverse event profile, drug interactions, others as applicable
• Agents that will be reviewed
  • Remdesivir
  • Chloroquine/Hydroxychloroquine
  • Lopinavir/Ritonavir
  • Ribavirin
  • Tocilizumab

What we won’t be deep-diving into
• Influenza mainstays:
  • Oseltamivir
  • Baloxavir

Nitazoxanide
Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 3 trial
Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness

## The Corticosteroid Controversy

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.

### Treatment of Severe Acute Respiratory Syndrome With Glucocorticoids

- Anakinra
- Galidesivir
- Arbidol
- Umifenovir
- Griffithsin
- Baricitinib
- IVIG
- Bevacizumab
- Nelfinavir
- Brilacidin
- Niclosamide
- Convalescent plasma
- REGN3048
- Darunavir/cobicistat
- Sofosbuvir
- Disulfiram
- TZLS-501
- Eculizumab
- Vitamin C
- Favipiravir
- XueBiJing

## Everything else in the world....

- Analgesics
- Antimicrobials
- Antivirals
- Convalescent plasma
- REGN3048
- Darunavir/cobicistat
- Sofosbuvir
- Disulfiram
- TZLS-501
- Eculizumab
- Vitamin C
- Favipiravir
- XueBiJing

## Stay Tuned

- This is a fluid and dynamic situation
- We will update as appropriate as more data become available
- www.sidp.org
- If you think we should cover something else, we are open to suggestions
- sidpaffinitystrategies.com
- We are working on other resources as well